President Trump Say In A Social Media Post That The University Of Miami Shared Its 1994 Ibogaine Investigational New Drug Application With The Government, Which Will Help Accelerate Development As A Medical Treatment In The U.S.

This Apogee Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Analysts changed outlooks on top stocks. Raymond James downgraded ONON, Deutsche Bank downgraded ATAI, BTIG downgraded APGE.

CoreWeave To Rally Around 95%? Here Are 10 Top Analyst Forecasts For Wednesday

Wall Street analysts change outlook on top names. HC Wainwright raises price target for Belite Bio, while B of A cuts Lumentum's target.

Deutsche Bank Downgrades AtaiBeckley to Hold, Lowers Price Target to $8

Deutsche Bank analyst David Hoang downgrades AtaiBeckley (NASDAQ:ATAI) from Buy to Hold and lowers the price target from $12 to $8.

Shares if ibogaine-related biotech companies are trading higher after President Trump said in a social media post that the University of Miami shared its 1994 ibogaine Investigational New Drug Application with the government, which will help accelerate development as a medical treatment in the U.S.

Silo Pharma Enters Asset Purchase Agreement With Parkview Consulting On August 18, 2026; Issues 165,000 Shares As Consideration For Asset Purchase

-SEC Filing

8-K filing — Silo Pharma, Inc. (SILO)

Filed: 2026-08-19 AccNo: 0001213900-26-091783 Size: 235 KB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 9.01: Financial Statements and Exhibits